280 related articles for article (PubMed ID: 33195396)
41. Frequency of pathogenic germline mutation in CHEK2, PALB2, MRE11, and RAD50 in patients at high risk for hereditary breast cancer.
Kim H; Cho DY; Choi DH; Oh M; Shin I; Park W; Huh SJ; Nam SJ; Lee JE; Kim SW
Breast Cancer Res Treat; 2017 Jan; 161(1):95-102. PubMed ID: 27783279
[TBL] [Abstract][Full Text] [Related]
42. Classification of VUS and unclassified variants in
Sinha S; Wang SM
Comput Struct Biotechnol J; 2020; 18():723-736. PubMed ID: 32257056
[TBL] [Abstract][Full Text] [Related]
43. Reclassification of
Lee JS; Oh S; Park SK; Lee MH; Lee JW; Kim SW; Son BH; Noh DY; Lee JE; Park HL; Kim MJ; Cho SI; Lee YK; Park SS; Seong MW
J Med Genet; 2018 Dec; 55(12):794-802. PubMed ID: 30415210
[TBL] [Abstract][Full Text] [Related]
44. Massively Parallel Functional Analysis of BRCA1 RING Domain Variants.
Starita LM; Young DL; Islam M; Kitzman JO; Gullingsrud J; Hause RJ; Fowler DM; Parvin JD; Shendure J; Fields S
Genetics; 2015 Jun; 200(2):413-22. PubMed ID: 25823446
[TBL] [Abstract][Full Text] [Related]
45. Using Co-segregation and Loss of Heterozygosity Analysis to Define the Pathogenicity of Unclassified Variants in Hereditary Breast Cancer Patients.
Grasel RS; Felicio PS; de Paula AE; Campacci N; Garcia FAO; de Andrade ES; Evangelista AF; Fernandes GC; Sabato CDS; De Marchi P; Souza CP; de Paula CAA; Torrezan GT; Galvão HCR; Carraro DM; Palmero EI
Front Oncol; 2020; 10():571330. PubMed ID: 33134171
[TBL] [Abstract][Full Text] [Related]
46. In silico, in vitro and case-control analyses as an effective combination for analyzing BRCA1 and BRCA2 unclassified variants in a population-based sample.
Rodríguez-Balada M; Roig B; Martorell L; Melé M; Salvat M; Vilella E; Borràs J; Gumà J
Cancer Genet; 2016 Nov; 209(11):487-492. PubMed ID: 27886673
[TBL] [Abstract][Full Text] [Related]
47. A computational model for classification of BRCA2 variants using mouse embryonic stem cell-based functional assays.
Biswas K; Lipton GB; Stauffer S; Sullivan T; Cleveland L; Southon E; Reid S; Magidson V; Iversen ES; Sharan SK
NPJ Genom Med; 2020 Dec; 5(1):52. PubMed ID: 33293522
[TBL] [Abstract][Full Text] [Related]
48. A high-throughput functional complementation assay for classification of BRCA1 missense variants.
Bouwman P; van der Gulden H; van der Heijden I; Drost R; Klijn CN; Prasetyanti P; Pieterse M; Wientjens E; Seibler J; Hogervorst FB; Jonkers J
Cancer Discov; 2013 Oct; 3(10):1142-55. PubMed ID: 23867111
[TBL] [Abstract][Full Text] [Related]
49. Computational Tools for Splicing Defect Prediction in Breast/Ovarian Cancer Genes: How Efficient Are They at Predicting RNA Alterations?
Moles-Fernández A; Duran-Lozano L; Montalban G; Bonache S; López-Perolio I; Menéndez M; Santamariña M; Behar R; Blanco A; Carrasco E; López-Fernández A; Stjepanovic N; Balmaña J; Capellá G; Pineda M; Vega A; Lázaro C; de la Hoya M; Diez O; Gutiérrez-Enríquez S
Front Genet; 2018; 9():366. PubMed ID: 30233647
[No Abstract] [Full Text] [Related]
50. Multigene Panel Testing Detects Equal Rates of Pathogenic BRCA1/2 Mutations and has a Higher Diagnostic Yield Compared to Limited BRCA1/2 Analysis Alone in Patients at Risk for Hereditary Breast Cancer.
Kapoor NS; Curcio LD; Blakemore CA; Bremner AK; McFarland RE; West JG; Banks KC
Ann Surg Oncol; 2015 Oct; 22(10):3282-8. PubMed ID: 26219241
[TBL] [Abstract][Full Text] [Related]
51. Germline CHEK2 Gene Mutations in Hereditary Breast Cancer Predisposition - Mutation Types and their Biological and Clinical Relevance.
Kleiblová P; Stolařová L; Křížová K; Lhota F; Hojný J; Zemánková P; Havránek O; Vočka M; Černá M; Lhotová K; Borecká M; Janatová M; Soukupová J; Ševčík J; Zimovjanová M; Kotlas J; Panczak A; Veselá K; Červenková J; Schneiderová M; Burócziová M; Burdová K; Stránecký V; Foretová L; Macháčková E; Tavandzis S; Kmoch S; Macůrek L; Kleibl Z
Klin Onkol; 2019; 32(Supplementum2):36-50. PubMed ID: 31409080
[TBL] [Abstract][Full Text] [Related]
52. PALB2 mutations in BRCA1/2-mutation negative breast and ovarian cancer patients from Poland.
Kluska A; Balabas A; Piatkowska M; Czarny K; Paczkowska K; Nowakowska D; Mikula M; Ostrowski J
BMC Med Genomics; 2017 Mar; 10(1):14. PubMed ID: 28279176
[TBL] [Abstract][Full Text] [Related]
53. Inherited breast cancer predisposition in Asians: multigene panel testing outcomes from Singapore.
Wong ESY; Shekar S; Met-Domestici M; Chan C; Sze M; Yap YS; Rozen SG; Tan MH; Ang P; Ngeow J; Lee ASG
NPJ Genom Med; 2016; 1():15003. PubMed ID: 29263802
[TBL] [Abstract][Full Text] [Related]
54. PALB2 mutations 1592delT and 229delT are not present in Korean breast cancer patients negative for BRCA1 and BRCA2 mutations.
Kim JH; Choi DH; Cho DY; Ahn SH; Son BH; Haffty BG
Breast Cancer Res Treat; 2010 Jul; 122(1):303-6. PubMed ID: 20213081
[TBL] [Abstract][Full Text] [Related]
55. Heterozygous PALB2 c.1592delT mutation channels DNA double-strand break repair into error-prone pathways in breast cancer patients.
Obermeier K; Sachsenweger J; Friedl TW; Pospiech H; Winqvist R; Wiesmüller L
Oncogene; 2016 Jul; 35(29):3796-806. PubMed ID: 26640152
[TBL] [Abstract][Full Text] [Related]
56. Clinical Management of Patients at Risk for Hereditary Breast Cancer with Variants of Uncertain Significance in the Era of Multigene Panel Testing.
Chang J; Seng S; Yoo J; Equivel P; Lum SS
Ann Surg Oncol; 2019 Oct; 26(10):3389-3396. PubMed ID: 31342386
[TBL] [Abstract][Full Text] [Related]
57. Double PALB2 and BRCA1/BRCA2 mutation carriers are rare in breast cancer and breast-ovarian cancer syndrome families from the French Canadian founder population.
Ancot F; Arcand SL; Mes-Masson AM; Provencher DM; Tonin PN
Oncol Lett; 2015 Jun; 9(6):2787-2790. PubMed ID: 26137147
[TBL] [Abstract][Full Text] [Related]
58. [PALB2 as Another Candidate Gene for Genetic Testing in Patients with Hereditary Breast Cancer in Czech Republic].
Janatová M; Borecká M; Soukupová J; Kleiblová P; Stříbrná J; Vočka M; Zemánková P; Panczak A; Veselá K; Souček P; Foretová L; Kleibl Z
Klin Onkol; 2016; 29 Suppl 1():S31-4. PubMed ID: 26691940
[TBL] [Abstract][Full Text] [Related]
59. Alternative transcript imbalance underlying breast cancer susceptibility in a family carrying PALB2 c.3201+5G>T.
Duran-Lozano L; Montalban G; Bonache S; Moles-Fernández A; Tenés A; Castroviejo-Bermejo M; Carrasco E; López-Fernández A; Torres-Esquius S; Gadea N; Stjepanovic N; Balmaña J; Gutiérrez-Enríquez S; Diez O
Breast Cancer Res Treat; 2019 Apr; 174(2):543-550. PubMed ID: 30552643
[TBL] [Abstract][Full Text] [Related]
60. Missense Variants of Uncertain Significance: A Powerful Genetic Tool for Function Discovery with Clinical Implications.
Sessa G; Ehlén Å; von Nicolai C; Carreira A
Cancers (Basel); 2021 Jul; 13(15):. PubMed ID: 34359619
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
